These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

234 related items for PubMed ID: 27644192

  • 1. Efficacy of pimobendan on survival and reoccurrence of pulmonary edema in canine congestive heart failure.
    Mizuno M, Yamano S, Chimura S, Hirakawa A, Takusagawa Y, Sawada T, Maetani S, Takahashi A, Mizuno T, Harada K, Shinoda A, Uchida S, Takeuchi J, Mizukoshi T, Endo M, Uechi M.
    J Vet Med Sci; 2017 Jan 20; 79(1):29-34. PubMed ID: 27644192
    [Abstract] [Full Text] [Related]

  • 2. Effect of pimobendan or benazepril hydrochloride on survival times in dogs with congestive heart failure caused by naturally occurring myxomatous mitral valve disease: the QUEST study.
    Häggström J, Boswood A, O'Grady M, Jöns O, Smith S, Swift S, Borgarelli M, Gavaghan B, Kresken JG, Patteson M, Ablad B, Bussadori CM, Glaus T, Kovacević A, Rapp M, Santilli RA, Tidholm A, Eriksson A, Belanger MC, Deinert M, Little CJ, Kvart C, French A, Rønn-Landbo M, Wess G, Eggertsdottir AV, O'Sullivan ML, Schneider M, Lombard CW, Dukes-McEwan J, Willis R, Louvet A, DiFruscia R.
    J Vet Intern Med; 2008 Jan 20; 22(5):1124-35. PubMed ID: 18638016
    [Abstract] [Full Text] [Related]

  • 3. Effect of Pimobendan in Dogs with Preclinical Myxomatous Mitral Valve Disease and Cardiomegaly: The EPIC Study-A Randomized Clinical Trial.
    Boswood A, Häggström J, Gordon SG, Wess G, Stepien RL, Oyama MA, Keene BW, Bonagura J, MacDonald KA, Patteson M, Smith S, Fox PR, Sanderson K, Woolley R, Szatmári V, Menaut P, Church WM, O'Sullivan ML, Jaudon JP, Kresken JG, Rush J, Barrett KA, Rosenthal SL, Saunders AB, Ljungvall I, Deinert M, Bomassi E, Estrada AH, Fernandez Del Palacio MJ, Moise NS, Abbott JA, Fujii Y, Spier A, Luethy MW, Santilli RA, Uechi M, Tidholm A, Watson P.
    J Vet Intern Med; 2016 Nov 20; 30(6):1765-1779. PubMed ID: 27678080
    [Abstract] [Full Text] [Related]

  • 4. Short-term hemodynamic and neuroendocrine effects of pimobendan and benazapril in dogs with myxomatous mitral valve disease and congestive heart failure.
    Häggström J, Lord PF, Höglund K, Ljungvall I, Jöns O, Kvart C, Hansson K.
    J Vet Intern Med; 2013 Nov 20; 27(6):1452-62. PubMed ID: 24128373
    [Abstract] [Full Text] [Related]

  • 5. Efficacy and safet of pimobendan in canine heart failure caused by myxomatous mitral valve disease.
    Smith PJ, French AT, Van Israël N, Smith SG, Swift ST, Lee AJ, Corcoran BM, Dukes-McEwan J.
    J Small Anim Pract; 2005 Mar 20; 46(3):121-30. PubMed ID: 15789807
    [Abstract] [Full Text] [Related]

  • 6. Longitudinal analysis of quality of life, clinical, radiographic, echocardiographic, and laboratory variables in dogs with myxomatous mitral valve disease receiving pimobendan or benazepril: the QUEST study.
    Häggström J, Boswood A, O'Grady M, Jöns O, Smith S, Swift S, Borgarelli M, Gavaghan B, Kresken JG, Patteson M, Åblad B, Bussadori CM, Glaus T, Kovačević A, Rapp M, Santilli RA, Tidholm A, Eriksson A, Belanger MC, Deinert M, Little CJ, Kvart C, French A, Rønn-Landbo M, Wess G, Eggertsdottir A, Lynne O'Sullivan M, Schneider M, Lombard CW, Dukes-McEwan J, Willis R, Louvet A, DiFruscia R.
    J Vet Intern Med; 2013 Mar 20; 27(6):1441-51. PubMed ID: 24010489
    [Abstract] [Full Text] [Related]

  • 7. Effect of pimobendan on the incidence of arrhythmias in small breed dogs with myxomatous mitral valve degeneration.
    Lake-Bakaar GA, Singh MK, Kass PH, Griffiths LG.
    J Vet Cardiol; 2015 Jun 20; 17(2):120-8. PubMed ID: 26007710
    [Abstract] [Full Text] [Related]

  • 8. Longitudinal Analysis of Quality of Life, Clinical, Radiographic, Echocardiographic, and Laboratory Variables in Dogs with Preclinical Myxomatous Mitral Valve Disease Receiving Pimobendan or Placebo: The EPIC Study.
    Boswood A, Gordon SG, Häggström J, Wess G, Stepien RL, Oyama MA, Keene BW, Bonagura J, MacDonald KA, Patteson M, Smith S, Fox PR, Sanderson K, Woolley R, Szatmári V, Menaut P, Church WM, O'Sullivan ML, Jaudon JP, Kresken JG, Rush J, Barrett KA, Rosenthal SL, Saunders AB, Ljungvall I, Deinert M, Bomassi E, Estrada AH, Fernandez Del Palacio MJ, Moise NS, Abbott JA, Fujii Y, Spier A, Luethy MW, Santilli RA, Uechi M, Tidholm A, Schummer C, Watson P.
    J Vet Intern Med; 2018 Jan 20; 32(1):72-85. PubMed ID: 29214723
    [Abstract] [Full Text] [Related]

  • 9. Survival and echocardiographic data in dogs with congestive heart failure caused by mitral valve disease and treated by multiple drugs: a retrospective study of 21 cases.
    de Madron E, King JN, Strehlau G, White RV.
    Can Vet J; 2011 Nov 20; 52(11):1219-25. PubMed ID: 22547843
    [Abstract] [Full Text] [Related]

  • 10. Clinical findings and survival time in dogs with advanced heart failure.
    Beaumier A, Rush JE, Yang VK, Freeman LM.
    J Vet Intern Med; 2018 May 20; 32(3):944-950. PubMed ID: 29635788
    [Abstract] [Full Text] [Related]

  • 11. Effect of prespecified therapy escalation on plasma NT-proBNP concentrations in dogs with stable congestive heart failure due to myxomatous mitral valve disease.
    Hezzell MJ, Block CL, Laughlin DS, Oyama MA.
    J Vet Intern Med; 2018 Sep 20; 32(5):1509-1516. PubMed ID: 30216549
    [Abstract] [Full Text] [Related]

  • 12. Pimobendan in heart failure therapy--a silver bullet?
    Gordon SG, Miller MW, Saunders AB.
    J Am Anim Hosp Assoc; 2006 Sep 20; 42(2):90-3. PubMed ID: 16527909
    [Abstract] [Full Text] [Related]

  • 13. Evaluation of pimobendan and N-terminal probrain natriuretic peptide in the treatment of pulmonary hypertension secondary to degenerative mitral valve disease in dogs.
    Atkinson KJ, Fine DM, Thombs LA, Gorelick JJ, Durham HE.
    J Vet Intern Med; 2009 Sep 20; 23(6):1190-6. PubMed ID: 19780931
    [Abstract] [Full Text] [Related]

  • 14. Effect of pimobendan on case fatality rate in Doberman Pinschers with congestive heart failure caused by dilated cardiomyopathy.
    O'Grady MR, Minors SL, O'Sullivan ML, Horne R.
    J Vet Intern Med; 2008 Sep 20; 22(4):897-904. PubMed ID: 18537880
    [Abstract] [Full Text] [Related]

  • 15. Pimobendan and its use in treating canine congestive heart failure.
    Bowles D, Fry D.
    Compend Contin Educ Vet; 2011 Nov 20; 33(11):E1. PubMed ID: 22101450
    [Abstract] [Full Text] [Related]

  • 16. Use of pimobendan in 170 cats (2006-2010).
    Macgregor JM, Rush JE, Laste NJ, Malakoff RL, Cunningham SM, Aronow N, Hall DJ, Williams J, Price LL.
    J Vet Cardiol; 2011 Dec 20; 13(4):251-60. PubMed ID: 22030289
    [Abstract] [Full Text] [Related]

  • 17. Efficacy of adding ramipril (VAsotop) to the combination of furosemide (Lasix) and pimobendan (VEtmedin) in dogs with mitral valve degeneration: The VALVE trial.
    Wess G, Kresken JG, Wendt R, Gaugele J, Killich M, Keller L, Simak J, Holler P, Bauer A, Küchenhof H, Glaus T.
    J Vet Intern Med; 2020 Nov 20; 34(6):2232-2241. PubMed ID: 32945575
    [Abstract] [Full Text] [Related]

  • 18. Evaluation of a fixed-dose combination of benazepril and pimobendan in dogs with congestive heart failure: a randomized non-inferiority clinical trial.
    King JN, Hirakawa A, Sonobe J, Otaki H, Sakakibara N, Seewald W, Forster S.
    J Vet Sci; 2018 Jan 31; 19(1):117-128. PubMed ID: 28693297
    [Abstract] [Full Text] [Related]

  • 19. Effect of oral administration of pimobendan in cats with heart failure.
    Gordon SG, Saunders AB, Roland RM, Winter RL, Drourr L, Achen SE, Hariu CD, Fries RC, Boggess MM, Miller MW.
    J Am Vet Med Assoc; 2012 Jul 01; 241(1):89-94. PubMed ID: 22720992
    [Abstract] [Full Text] [Related]

  • 20. Effects of pimobendan on myocardial perfusion and pulmonary transit time in dogs with myxomatous mitral valve disease: a pilot study.
    Apple SM, Menciotti G, Braz-Ruivo L, Crosara S, Häggström J, Borgarelli M.
    Aust Vet J; 2016 Sep 01; 94(9):324-8. PubMed ID: 27569835
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.